SCHEMBL353126

SCHEMBL353126

CCNC(=O)c1c(C)noc1C

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.60
ALOX15 P16050 3/20 0.57
TSHR P16473 2/20 0.57
HSD17B10 Q99714 2/20 0.57
USP2 O75604 1/20 0.57
ALDH1A1 P00352 6/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KMT2A Q03164 5/20 0.50
TP53 P04637 1/20 0.50
GFER P55789 1/20 0.48
MEN1 O00255 3/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
AGTR1 P30556 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6360331 0.86 TSHR (0.59) GAAALOX15TSHRHSD17B10USP2
SCHEMBL14044533 0.82 GAA (0.61) GAAALOX15TSHRHSD17B10USP2
SCHEMBL21617368 0.81 GAA (0.55) GAAALOX15TSHRHSD17B10USP2
SCHEMBL353328 0.79 ALDH1A1 (0.56) GAAALOX15TSHRHSD17B10USP2
SCHEMBL8919079 0.75 GAA (0.47) GAAALOX15TSHRHSD17B10USP2
SCHEMBL8919058 0.75 GAA (0.47) GAAALOX15TSHRHSD17B10USP2
SCHEMBL5533585 0.75 L3MBTL1 (0.69) GAATSHRALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL14665121 0.75 ATM (0.45) GAAALOX15TSHRHSD17B10USP2
SCHEMBL13101603 0.74 ALDH1A1 (0.51) GAAALOX15TSHRHSD17B10USP2
SCHEMBL12376698 0.74 POLB (0.61) GAAALOX15TSHRHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 GAA 2295/4885ALOX15 2243/4885TSHR 638/4885
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA GAA 602/4885ALOX15 4600/4885TSHR 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.